Focused On-demand Library for Protein YIF1B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q5BJH7

UPID:

YIF1B_HUMAN

Alternative names:

YIP1-interacting factor homolog B

Alternative UPACC:

Q5BJH7; H7BXS8; Q5JPC2; Q8WY70; Q96C02; Q96IC4

Background:

Protein YIF1B, also known as YIP1-interacting factor homolog B, plays a crucial role in cellular transport mechanisms, specifically in the endoplasmic reticulum to Golgi vesicle-mediated transport. It is instrumental in maintaining the proper organization of the endoplasmic reticulum and the Golgi apparatus. Furthermore, YIF1B is vital for the targeting of neuronal dendrites receptors such as HTR1A and is implicated in the assembly of primary cilium and sperm flagellum, highlighting its significance in cellular structure and signaling.

Therapeutic significance:

YIF1B's association with Kaya-Barakat-Masson syndrome, a neurodevelopmental disorder characterized by a spectrum of impairments including intellectual development and motor coordination, underscores its therapeutic significance. Understanding the role of Protein YIF1B could open doors to potential therapeutic strategies for treating or managing this syndrome and possibly other related neurological disorders.